339 related articles for article (PubMed ID: 34118298)
1. Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kabashima K; Oda M; Nagata T
J Am Acad Dermatol; 2021 Oct; 85(4):854-862. PubMed ID: 34118298
[TBL] [Abstract][Full Text] [Related]
2. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T
J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Oda M; Kabashima K; Nagata T
J Allergy Clin Immunol; 2019 Dec; 144(6):1575-1583. PubMed ID: 31425780
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Murata R; Kaino H; Nagata T
J Dermatol; 2020 Feb; 47(2):114-120. PubMed ID: 31820485
[TBL] [Abstract][Full Text] [Related]
5. Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study.
Nakagawa H; Igarashi A; Saeki H; Kabashima K; Tamaki T; Kaino H; Miwa Y
Allergol Int; 2024 Jan; 73(1):137-142. PubMed ID: 37100717
[TBL] [Abstract][Full Text] [Related]
6. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
[TBL] [Abstract][Full Text] [Related]
7. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
Worm M; Thyssen JP; Schliemann S; Bauer A; Shi VY; Ehst B; Tillmann S; Korn S; Resen K; Agner T
Br J Dermatol; 2022 Jul; 187(1):42-51. PubMed ID: 35084738
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study.
Worm M; Bauer A; Elsner P; Mahler V; Molin S; Nielsen TSS
Br J Dermatol; 2020 May; 182(5):1103-1110. PubMed ID: 31466119
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.
Nakagawa H; Nemoto O; Igarashi A; Nagata T
Br J Dermatol; 2018 Feb; 178(2):424-432. PubMed ID: 28960254
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
Nakagawa H; Nemoto O; Yamada H; Nagata T; Ninomiya N
J Dermatol; 2018 Jun; 45(6):701-709. PubMed ID: 29665062
[TBL] [Abstract][Full Text] [Related]
11. Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial.
Saeki H; Ito K; Yokota D; Tsubouchi H
J Am Acad Dermatol; 2022 Mar; 86(3):607-614. PubMed ID: 34710557
[TBL] [Abstract][Full Text] [Related]
12. Real-world efficacy of proactive maintenance treatment with delgocitinib ointment twice weekly in adult patients with atopic dermatitis.
Suehiro M; Numata T; Murakami E; Takahashi M; Saito R; Morioke S; Kamegashira A; Takahagi S; Hide M; Tanaka A
Dermatol Ther; 2022 Jul; 35(7):e15526. PubMed ID: 35441769
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
Schachner LA; Lamerson C; Sheehan MP; Boguniewicz M; Mosser J; Raimer S; Shull T; Jaracz E;
Pediatrics; 2005 Sep; 116(3):e334-42. PubMed ID: 16140675
[TBL] [Abstract][Full Text] [Related]
14. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
Bissonnette R; Papp KA; Poulin Y; Gooderham M; Raman M; Mallbris L; Wang C; Purohit V; Mamolo C; Papacharalambous J; Ports WC
Br J Dermatol; 2016 Nov; 175(5):902-911. PubMed ID: 27423107
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis.
Ma L; Zhang L; Kobayashi M; Tao X; Qian Q; Cheng H; Liu S; Zhou Y; Chen Y; Zhang J
J Dermatol; 2023 Jul; 50(7):847-855. PubMed ID: 37154471
[TBL] [Abstract][Full Text] [Related]
16. Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.
Saeki H; Baba N; Oshiden K; Abe Y; Tsubouchi H
J Dermatol; 2020 Jan; 47(1):17-24. PubMed ID: 31713267
[TBL] [Abstract][Full Text] [Related]
17. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.
Mikhaylov D; Glickman JW; Del Duca E; Nia J; Hashim P; Singer GK; Posligua AL; Florek AG; Ibler E; Hagstrom EL; Estrada Y; Rangel SM; Colavincenzo M; Paller AS; Guttman-Yassky E
Arch Dermatol Res; 2023 Mar; 315(2):181-189. PubMed ID: 35230488
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
19. Effects of Delgocitinib Ointment 0.5% on the Normal Mouse Skin and Epidermal Tight Junction Proteins in Comparison With Topical Corticosteroids.
Anagawa-Nakamura A; Ryoke K; Yasui Y; Shoda T; Sugai S
Toxicol Pathol; 2020 Dec; 48(8):1008-1016. PubMed ID: 33334258
[TBL] [Abstract][Full Text] [Related]
20. Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
Luger TA; Hebert AA; Zaenglein AL; Silverberg JI; Tan H; Ports WC; Zielinski MA
Paediatr Drugs; 2022 Mar; 24(2):175-183. PubMed ID: 35292919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
